For Immediate Release (2004)Full Document 

Start of Preview




Investor Contacts:   Media Contacts:

Dan Spiegelman


John Bluth

SVP & Chief Financial Officer


Senior Director, Corporate Communications

(650) 384-8509


(650) 384-8850

Christopher Chai


Carol Harrison

Treasurer & Executive Director, Investor Relations



(650) 384-8560


(212) 453-2442




PALO ALTO, Calif., August 2, 2004 — CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population. The study is being conducted under the U.S. Food and Drug Administration’s (FDA) special protocol assessment (SPA) process, as announced on June 2, 2004.


“We are very excited to have initiated this approval-enabling study. In addition to the SPA agreement we have in place for this study, we also have a second SPA in place for the MERLIN trial, which could support potential approval of Ranexa as first-line therapy in chronic angina, and could also result in approval for treatment of acute coronary syndromes (ACS) and for long-term prevention of ACS,” said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics, Inc.


If approved, Ranexa would represent the first new class of anti-anginal therapy in the United States in more than 25 years. Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain. It affects approximately 6.8 million people in the United States.

End of Preview